Breast Cancer
Breast cancer, a malignant tumor originating in the epithelial cells of the breast, is one of the most common cancers among women and one of the leading causes of cancer deaths in women. The incidence of breast cancer is related to a number of factors, including heredity, age, hormone levels, and lifestyle. Based on the characteristics of tumor cells, breast cancer can be classified into different subtypes, such as hormone receptor positive (ER+/PR+), human epidermal growth factor receptor 2 (HER2+), and triple-negative breast cancer (TNBC).
In recent years, significant progress has been made in breast cancer treatment and drug development. Especially in the field of targeted therapy and immunotherapy, the continuous emergence of new drugs and therapies has brought more treatment options and better prognosis for patients.
Targeted therapy drugs:
● HER2 positive breast cancer
The treatment of HER2-positive breast cancer has made significant progress in the past few years.ADC (Antibody Drug Coupling Compound)-based drug therapy is an important breakthrough in the treatment of HER2-positive breast cancer. For example, DS-8201 (Trastuzumab Deruxtecan), an ADC drug targeting HER2, has shown potential efficacy in clinical trials in patients with low HER2 expression and HER2-negative breast cancer.67 Additionally, T-DM1 (Trastuzumab Emtansine) and T-DXd ( Trastuzumab Deruxtecan) have also been successful in the treatment of HER2-positive breast cancer.
● Hormone receptor positive breast cancer
For hormone receptor-positive breast cancer, the development of CDK4/6 inhibitors such as abemaciclib, dalciclib, and ribociclib has provided new treatment options for patients. These drugs slow the growth and spread of tumor cells by inhibiting key regulators of the cell cycle.
● Triple Negative Breast Cancer
Triple-negative breast cancer (TNBC) is one of the more difficult subtypes to treat because it lacks hormone receptors and HER2 expression. However, immunotherapy has made progress in this area, for example PD-1/PD-L1 inhibitors have shown potential in the treatment of TNBC.
Immunotherapy drugs:
Immunotherapy is another important advance in the field of breast cancer treatment. Immune checkpoint inhibitors, such as PD-1 and PD-L1 inhibitors, have shown some efficacy in the treatment of triple negative breast cancer. In addition, researchers are exploring strategies to use immunotherapy in conjunction with other therapies to improve treatment outcomes.
Breast Cancer Drug Targets
Breast Cancer Drug Target Related Products
● Target Proteins
Measured by its binding ability in a functional ELISA. Immobilized HER2 at 2 μg/ml can bind Trastuzumab, the EC50 is 2.179-2.825 ng/ml.
Measured by its binding ability in a functional ELISA. Immobilized PD-1 at 2 μg/ml can bind Anti-PD-1 recombinant antibody, the EC50 of human PD-1 protein is 6.087-7.854 ng/ml.
Measured by its binding ability in a functional ELISA. Immobilized PD-L1 at 2 μg/ml can bind Anti- PD-L1 mouse monoclonal antibody (CSB-MA878942A1m, antigen from E.coli), the EC50 of human PD-L1 protein is 1.252-1.653 ng/mL
Measured in cell activity assay using U937 cells, the EC50 for this effect is 190.2-298.6 ng/ml.
Measured by its binding ability in a functional ELISA. Immobilized NRG1 (CSB-MP016077HU1(F6)) at 2 μg/ml can bind human ERBB3, the EC50 is 12.32-15.74 ng/ml.
Measured by its binding ability in a functional ELISA. Immobilized CD152 at 2 μg/ml can bind Anti-CD152 rabbit monoclonal antibody (CSB-RA213310A0HU), the EC50 of human CD152 protein is 27.14-34.82 ng/ml.
Human SIRPA protein His/Myc tag (CSB-MP021334HU) captured on COOH chip can bind Human CD47 protein Fc tag (CSB-MP004940HU) with an affinity constant of 19.1 nM as detected by LSPR Assay.
Human EGF protein captured on COOH chip can bind Human EGFR protein, his and Myc tag (CSB-MP007479HU) with an affinity constant of 11.9nM as detected by LSPR Assay.
